Enhancing the efficacy and selectivity of novel antimicrobial peptides against methicillin-resistant Staphylococcus...

Area of Science:

• Biochemistry
• Microbiology
• Drug Discovery

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) is a high-priority pathogen due to its resistance and biofilm formation.
• Conventional antibiotics are becoming less effective against MRSA, necessitating novel therapeutic strategies.
• Antimicrobial peptides (AMPs) offer a potential alternative, but their discovery is challenging.

Purpose of the Study:

• To computationally and experimentally evaluate AMPs for anti-MRSA activity, selectivity, and antibiofilm effects.
• To identify and optimize a novel AMP candidate for treating MRSA infections.
• To assess the efficacy of the optimized AMP against MRSA biofilms and its safety profile.

Main Methods:

• Utilized computational screening and experimental validation of AMPs.
• Assessed physicochemical properties, anti-MRSA activity against 10 clinical isolates, bacterial selectivity, and cytotoxicity.
• Evaluated antibiofilm effects using the transferable solid-phase pin lid method.

Main Results:

• Identified Temporin-PF (TPF) as a lead candidate, modified to TPF-M1 with an improved anti-MRSA score.
• TPF-M1 demonstrated enhanced killing activity and selectivity against MRSA with low human cell toxicity.
• TPF-M1 significantly reduced MRSA biofilm viability and disrupted biofilm structure at 20 µM.

Conclusions:

• AI-guided development can accelerate the discovery of effective AMPs against high-priority pathogens like MRSA.
• TPF-M1 is a promising candidate for novel anti-MRSA therapies, addressing both planktonic and biofilm forms.
• This approach highlights the potential of AMPs as a viable alternative to conventional antibiotics for combating drug-resistant bacteria.